Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Appoints Dr. Cedric Burg as Vice President and Head of Global Clinical Operations and Project Management

Building strong clinical team to effectively support robust clinical programsDr. Burg to leverage his international experience to expand the Company’s clinical trials globally BRANFORD, Conn., June ...
June 07, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer

BRANFORD, Conn., June 07, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
June 05, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

BRANFORD, Conn., June 05, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
June 04, 2018 08:30 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics and Nektar Therapeutics Present Preclinical Pancreatic Cancer Data for BXCL701, NKTR-214 and Anti-PD1 Combination Therapy at ASCO 2018 Annual Meeting

BXCL701 in Combination with NKTR-214 and anti-PD-1 Therapy Leads to Complete and Sustained Tumor Regression and Immune Memory in Pre-Clinical Syngeneic Models Results Support Further Development of...
May 18, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at 2018 UBS Global Healthcare Conference

BRANFORD, Conn., May 18, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
May 17, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting

BRANFORD, Conn., May 17, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
May 14, 2018 16:01 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update

BRANFORD, Conn., May 14, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...
April 26, 2018 08:30 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting

BRANFORD, Conn., April 26, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
April 19, 2018 08:30 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Ring the NASDAQ Stock Market Opening Bell on April 20, 2018

BRANFORD, Conn., April 19, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...